Dental caries
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Detection of Streptococcus mutans by PCR amplification of the spaP gene in teeth rendered caries free.
|
9699435 |
1998 |
Mesothelioma
|
0.010 |
GeneticVariation
|
disease |
LHGDN |
Transcriptome sequencing of malignant pleural mesothelioma tumors.
|
18303113 |
2008 |
Caries (morphologic abnormality)
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Detection of Streptococcus mutans by PCR amplification of the spaP gene in teeth rendered caries free.
|
9699435 |
1998 |
Prostatic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.
|
17013881 |
2007 |
Malignant neoplasm of prostate
|
0.300 |
Biomarker
|
disease |
CTD_human |
Identification of genes potentially involved in the acquisition of androgen-independent and metastatic tumor growth in an autochthonous genetically engineered mouse prostate cancer model.
|
17013881 |
2007 |
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
In a xenograft tumor model in which TGF-β was previously shown to elicit tumor-promoting effects, PDZK1IP1 gain of function decreased tumor size and increased survival rates.
|
30718277 |
2019 |
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Therefore, the protein cluster formed by the association of cMOAT, PDZK1, and MAP17 could play an important role in the cellular mechanisms associated with multidrug resistance, and PDZK1 may represent a new target in cancer cells resistant to chemotherapeutic agents.
|
10496535 |
1999 |
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB.
|
28153862 |
2017 |
Tumor Progression
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
p38α limits the contribution of MAP17 to cancer progression in breast tumors.
|
22266858 |
2012 |
Tumor Progression
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Immunohistochemical analysis of MAP17 during cancer progression shows, at least in prostate and ovarian carcinomas, that overexpression of the protein strongly correlates with tumoral progression (P < 0.0001).
|
17426052 |
2007 |
Tumor Progression
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, MAP17 is correlated with tumour progression.
|
30119639 |
2018 |
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
The Cargo Protein MAP17 (PDZK1IP1) Regulates the Cancer Stem Cell Pool Activating the Notch Pathway by Abducting NUMB.
|
28153862 |
2017 |
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
EGFR-TKI resistance and MAP17 are associated with cancer stem cell like properties.
|
29616128 |
2018 |
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Therefore, the protein cluster formed by the association of cMOAT, PDZK1, and MAP17 could play an important role in the cellular mechanisms associated with multidrug resistance, and PDZK1 may represent a new target in cancer cells resistant to chemotherapeutic agents.
|
10496535 |
1999 |
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NFκB Activation in Breast Cancer.
|
25837675 |
2015 |
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NFκB Activation in Breast Cancer.
|
25837675 |
2015 |
Adenoma
|
0.010 |
Biomarker
|
group |
BEFREE |
CIMP-H (>1 marker positive) was significantly more frequent in SPAP, SA, and SCa compared with MVSP (P<0.05); CIMP-H was present in 10% of sTAs but was found more frequently in lTA (44.4%; OR 7.2; P=0.007) and TCa (38.9%; OR 5.8; P=0.007).
|
17122504 |
2006 |
Atrial Fibrillation
|
0.010 |
Biomarker
|
disease |
BEFREE |
Paroxysmal AF comparing to permanent AF and SR individuals had higher estimated SPAP (56 versus 48 versus 47 mmHg, <i>p</i> = 0.01) and shorter ACT (58 versus 65 versus 70 ms, <i>p</i> = 0.04).
|
28280732 |
2017 |
Dermatitis, Atopic
|
0.010 |
Biomarker
|
disease |
BEFREE |
Interestingly, MAP17 was originally reported to interact with PDZK1; in turn, the PDZK1 gene is localized within the atopic dermatitis-linked region on human chromosome 1q21.
|
19601982 |
2010 |
Eczema
|
0.010 |
Biomarker
|
disease |
BEFREE |
Interestingly, MAP17 was originally reported to interact with PDZK1; in turn, the PDZK1 gene is localized within the atopic dermatitis-linked region on human chromosome 1q21.
|
19601982 |
2010 |
Lung Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Our results indicate a potential prognostic role for MAP17 in lung tumours, with particular relevance in lung adenocarcinomas, and highlight the predictive pot0065ntial of this membrane-associated protein for platinum-based therapy and EGFR inhibitor efficacy.
|
30119639 |
2018 |
Multiple Myeloma
|
0.010 |
Biomarker
|
disease |
BEFREE |
To analyze whether MAP17 could also alter this process, we used the proteasome inhibitor bortezomib (Velcade, PS-341), which is approved for the treatment of multiple myeloma and mantle cell lymphoma, although it has a high rate of resistance emergence and poor efficacy in solid tumors.
|
25837675 |
2015 |
Rectal Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
In the present manuscript, we examined the values of MAP17 and pH2AX as surrogate biomarkers of the response in rectal tumors.
|
30250642 |
2018 |
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
In addition, we show that MAP17 expression predicts proteasome inhibitor efficacy in this context and that bortezomib, an FDA-approved drug, may be a novel therapeutic approach for MAP17-overexpressing lung adenocarcinomas.
|
30119639 |
2018 |
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Collectively these findings suggest that MAP17 serves a role in TKI resistance through regulation of CSCs in lung cancer.
|
29616128 |
2018 |